Oral PCSK9-inhibitor highly effective at reducing high levels of LDL cholesterol, studies show

Results from two early clinical studies show the first version of an oral PCSK9-inhibitor cholesterol-lowering medicine was well tolerated and highly effective at reducing high levels of LDL cholesterol, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2021.